Unlike UFH, routine monitoring of anticoagulant effect is usually not required for LMWH due to its predictable pharmacokinetics. However, certain situations may warrant monitoring:
- Renal Impairment: Patients with reduced kidney function may require anti-Xa level monitoring to avoid accumulation and increased bleeding risk. - Pregnancy: Monitoring may be performed to ensure therapeutic levels are maintained. - Obesity or Underweight: Dose adjustments based on anti-Xa levels may be necessary.
